Current Research in Toxicology is a pioneering journal published by ELSEVIER that serves as a vital platform for disseminating cutting-edge research in the field of toxicology, spanning from biological impacts to pharmacological applications. With an ISSN of 2666-027X and an impressive Q2 ranking in key categories such as Applied Microbiology and Biotechnology, Health, Toxicology and Mutagenesis, and Toxicology, this journal underscores its commitment to high-quality research and significant contributions to the scientific community. Based in the Netherlands, Current Research in Toxicology aims to bridge the gap between academia and industry by providing rigorously peer-reviewed articles that cover a wide array of topics including novel methodologies, regulatory challenges, and emerging trends within the domain. The journal is accessible through various platforms, making it essential for researchers, professionals, and students eager to stay updated on the latest findings and advancements in toxicology. With a comprehensive focus on integrating theory with practical application, this journal is poised to influence future studies and policies in health and environmental science.

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

Welcome to BMC Pharmacology & Toxicology, a premier open-access journal dedicated to advancing the fields of pharmacology and toxicology. Published by BMC since 2012, this esteemed journal offers a platform for researchers, professionals, and students to disseminate cutting-edge research and innovative findings that explore the intricate interactions between drugs and biological systems. With its robust Q2 ranking in both general medicine and pharmacology categories for 2023, BMC Pharmacology & Toxicology is recognized for its significant contributions to the academic community, reflected in its strategic positioning within the 61st and 49th percentiles in Scopus rankings for related disciplines. The journal's commitment to open access ensures that vital research is accessible to a global audience, fostering collaboration and informed discussions. We invite you to engage with the latest studies, reviews, and innovative methodologies that shape the future of pharmacological and toxicological sciences.

CURRENT DRUG METABOLISM, published by Bentham Science Publishers Ltd, serves as a pivotal resource in the fields of Clinical Biochemistry and Pharmacology. With an ISSN of 1389-2002 and an E-ISSN of 1875-5453, this journal has carved a niche since its inception in 2000, offering in-depth research and reviews that bridge the gap between drug metabolism and its clinical applications. The journal finds itself positioned in the third quartile (Q3) for both Clinical Biochemistry and Pharmacology as of 2023, reflecting its significance within these scientific sectors, with Scopus rankings showcasing its role in advancing knowledge—rank #167 in Pharmacology and #66 in Clinical Biochemistry. Researchers and industry professionals are encouraged to contribute their findings, fostering a diverse platform that informs and inspires innovations in drug development and safety. While CURRENT DRUG METABOLISM operates under a traditional subscription model without open access, its rigorous peer-review process ensures the quality and integrity of the published work, making it indispensable for anyone engaged in drug research and biochemistry.

TOXICOLOGICAL SCIENCES, published by Oxford University Press, is a premier journal in the field of toxicology that has been a cornerstone of scientific discourse since its inception in 1981. With an impressive 2023 impact factor and ranked in the Q1 category for Toxicology, this journal is highly regarded among researchers, professionals, and students dedicated to pharmacology and toxicology. The journal is committed to advancing the understanding of toxicological science, covering a breadth of topics that include the mechanisms of toxicity, risk assessment, and the regulatory aspects affecting public health. With an ISSN of 1096-6080 and an E-ISSN of 1096-0929, TOXICOLOGICAL SCIENCES facilitates open access scholarly work, ensuring that critical research reaches a global audience and promotes collaborative learning. As it converges towards 2024, the journal remains pivotal in shaping the future of toxicology research, providing insights that are essential for developing safer chemicals and protecting environmental health.

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.

JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS is a crucial publication in the field of veterinary medicine, dedicated to advancing knowledge and practices related to pharmacology and therapeutic interventions in animals. Published by WILEY, this peer-reviewed journal has been a reliable source of innovative research since its inception in 1978, and it continues to play an integral role in shaping veterinary pharmacology through its commitment to high-quality scientific discourse. With an impact factor reflective of its robust academic standing, the journal is categorized in the Q3 quartile for Pharmacology and Q2 for Veterinary (miscellaneous) as of 2023, highlighting its relevance and significance within these domains. It is indexed in Scopus with commendable rankings, particularly in General Veterinary, where it ranks #45 out of 194, placing it in the 77th percentile. This journal not only offers a platform for original research articles but also caters to the dissemination of practical applications and reviews that are essential for veterinarians, researchers, and students alike in enhancing animal health and welfare. Although not an open-access publication, its contributions remain accessible to those engaged in the veterinary sciences through institutional subscriptions. The journal's enduring legacy and forward-looking approach make it a vital resource for anyone interested in veterinary therapeutics and pharmacology.

Frontiers in Toxicology, published by Frontiers Media SA, is a prominent open-access journal dedicated to advancing the understanding of toxicological science. Established in 2019, it serves as a vital forum for innovative research, offering insights into the pharmacological impacts and toxicological profiles of various substances. With its international reach based in Switzerland, this journal has quickly ascended in the academic community, achieving a notable Q1 ranking in Pharmacology, Toxicology and Pharmaceutics (Miscellaneous) and a Q2 ranking in Toxicology as of 2023. The journal is indexed in Scopus, where it ranks #8 out of 43 in its primary category, underscoring its influence and relevance in the field. The scope encompasses cutting-edge studies on the mechanisms of toxicity, including both human and environmental impacts, making it an essential resource for researchers, professionals, and students alike. By promoting open access to high-quality research, Frontiers in Toxicology plays a crucial role in enhancing knowledge sharing and fostering collaboration across disciplines.

Current Pharmaceutical Analysis, published by Bentham Science Publishers Ltd, is a vital resource for professionals and researchers in the fields of Pharmaceutical Science, Biochemistry, and Molecular Medicine. Established in 2006, this peer-reviewed journal aims to provide a platform for the latest advancements and analytical methodologies in pharmaceutical research and drug development. Over the years, it has garnered attention for its rigorous scrutiny and contributions to the landscape of pharmacology, evidenced by its quartile placements in various categories, most notably Q3 in Pharmaceutical Science. Despite its current rankings placing it in the lower quartile in several disciplines, the journal remains an essential venue for both emerging and established researchers seeking to disseminate their findings. With the widespread accessibility of its articles, researchers, professionals, and students can engage with cutting-edge studies to foster innovation in pharmaceutical analysis. For access to the latest research contributions, readers can explore the digital archive and stay updated on pivotal discussions shaping the future of the pharmaceutical sciences.

TOXICOLOGY IN VITRO is a premier journal published by PERGAMON-ELSEVIER SCIENCE LTD, focusing on the latest advancements in the field of toxicology, particularly through in vitro methodologies. With an ISSN of 0887-2333 and an E-ISSN of 1879-3177, this journal serves as a critical platform for researchers aiming to disseminate their findings in toxicology, emphasizing innovative approaches and applications in pharmacology and toxicology. Featuring a commendable impact factor and classified in the second quartile (Q2) for both Medicine (miscellaneous) and Toxicology in 2023, the journal holds a significant position within the academic community, ranking 41st out of 133 in the Toxicology category according to Scopus, representing the 69th percentile. Despite being a subscription-based publication, it continuously attracts submissions from leading scientists worldwide, fostering a vibrant exchange of scientific knowledge. Since its inception in 1987, TOXICOLOGY IN VITRO has consistently aimed to enhance understanding of toxicological challenges, making it an invaluable resource for professionals, students, and researchers dedicated to developing safer pharmaceuticals and understanding the biological pathways influenced by potential toxic agents.